Joost de Jong

Senior researcher

Maastricht University Medical Centre
Country flagNetherlands

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

Year:

2026

Background Huntington's Disease (HD) is a hereditary neurodegenerative disorder caused by a cytosine-adenine-guanine (CAG) repeat expansion (CAG > 35) in the Huntingtin ( HTT ) gene. Intermediate alleles (IAs, CAG = 27–35) are generally not associated with HD. However, IA carriers with symptoms have been reported in literature. Objective To review the existing literature on IAs, in order to provide an overview of the clinical phenotype of IA carriers. Methods Peer-reviewed articles published between 1993 and July 2024 from three databases (Embase, PubMed, and Web of Science) were included. Results In case reports, a high percentage (90%) of IA carriers was reported to have symptoms (HD-related and -unrelated), or abnormalities in neuroimaging. Cohort studies also reported evidence of symptoms in IA carriers, although most cohorts did not obtain significant differences compared to controls. Conclusion Based on this review, we argue that there is not enough evidence to draw a clear conclusion on the clinical phenotype of individuals carrying an intermediate allele of the HTT gene. Literature reports symptomatic IA carriers, but reported symptoms are non-specific and common in the general population. Additionally, the quality of the data is suboptimal, due to lack of detailed symptom descriptions, the absence of differential diagnoses, a selection bias, and a considerable publication bias towards IA carriers with symptoms. More research is needed to provide a better insight into the clinical phenotype of IA carriers.

Year:

2026

BACKGROUND: Hypertension is a major risk factor for cerebral small vessel disease (SVD), but the underlying mechanisms remain incompletely understood. Blood-brain barrier (BBB) leakage is hypothesized to be involved in SVD pathogenesis, but this was mainly demonstrated in older patients with established SVD on magnetic resonance imaging. We investigated BBB leakage in young patients with hypertension, at risk for SVD, compared with controls. METHODS: BBB leakage of gadolinium contrast agent was measured with 3T magnetic resonance imaging in 59 patients with hypertension (mean age, 35.8 ± 9.7 years; 54% female; mean blood pressure, 146/92 mm Hg) and 21 healthy controls (mean age, 29.9 ± 4.8 years; 52% female; mean blood pressure, 120/75 mm Hg). Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) was used to measure BBB leakage (leakage rate, Ki [min −1 ] and blood plasma volume fraction [ Vp ]). Linear regression adjusted for age and sex was used to compare BBB leakage between patients and controls. We additionally adjusted for the amended SVD score and white matter hyperintensity volume. We also compared patients with primary aldosteronism to those with hypertension due to other causes. RESULTS: Patients with hypertension had 17% higher BBB leakage ( Ki ) in the white matter ( P =0.049) and 15% in the gray matter ( P =0.070) compared with controls, independent of SVD burden. No differences were found in Vp or between patients with primary aldosteronism and other causes. CONCLUSIONS: Young patients with hypertension show BBB disruption independent of MRI–detectable SVD. This suggests a possible role of BBB dysfunction in SVD pathogenesis. Restoration of BBB integrity may be a relevant target for interventions in SVD, but longitudinal and intervention studies are needed to confirm causality. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06175663.

Year:

2025

Obsessive–compulsive disorder (OCD) manifests with diverse symptom constellations that likely arise from dysfunction in partially distinct neural circuits. Deep brain stimulation (DBS), paired with high-resolution connectomics, offers a unique window into these pathways in humans. Here, we analyzed clinical outcomes and stimulation sites from 77 treatment-refractory patients with OCD and 39 with Tourette’s syndrome (TS) exhibiting comorbid obsessive–compulsive behaviors (244 electrodes across 15 cohorts and eight targets). Engagement of the previously defined OCD response tract predicted global obsessive-compulsive symptom improvement across heterogeneous targets and diagnoses, spanning both OCD and TS. Beyond broad symptoms, obsessions, compulsions, anxiety, and depression mapped onto distinct yet overlapping subcircuits fragmenting the anterior limb of the internal capsule along a dorsoventral axis. This fine-scale architecture of OCD circuit dysfunction was reproducible across cross-validation schemes and patient subsets. Exploratory analyses identified additional subcircuits for cognitive control and flexibility. Global functional recovery was better explained by combined engagement of multiple symptom-specific rather than a single tract. Collectively, these findings illustrate how invasive neuromodulation can delineate a multi-symptom circuit taxonomy of compulsivity that may guide personalized neuromodulation.

Year:

2025

BACKGROUND: Blood-brain barrier (BBB) integrity is presumed to be impaired in hypertension, resulting from cerebral endothelial dysfunction. Hypertension precedes various cerebrovascular diseases, such as cerebral small vessel disease, and is a risk factor for developing neurodegenerative diseases for which BBB disruption is a preceding pathophysiological process. In this cross-sectional study, we investigated the relation between hypertension, current blood pressure, and BBB leakage in human subjects. METHODS: BBB leakage was determined in 22 patients with hypertension and 19 age- and sex-matched normotensive controls (median age [range], 65 [45–80] years; 19 men) using a sparsely time-sampled contrast-enhanced 7T magnetic resonance imaging protocol. Structural cerebral small vessel disease markers were visually rated. Multivariable regression analyses, adjusted for age, sex, cardiovascular risk factors, and cerebral small vessel disease markers, were performed to determine the relation between hypertension status, systolic and diastolic blood pressure, mean arterial pressure, drug treatment, and BBB leakage. RESULTS: Both hypertensive and normotensive participants showed mild scores of cerebral small vessel disease. BBB leakage did not differ between hypertensive and normotensive participants; however, it was significantly higher for systolic blood pressure, diastolic blood pressure, and mean arterial pressure in the cortex, and diastolic blood pressure and mean arterial pressure in the gray matter. Effectively treated patients showed less BBB leakage than those with current hypertension. CONCLUSIONS: BBB integrity in the total and cortical gray matter decreases with increasing blood pressure but is not related to hypertension status. These findings show that BBB disruption already occurs with increasing blood pressure, before the presence of overt cerebral tissue damage. Additionally, our results suggest that effective antihypertensive medication has a protective effect on the BBB. REGISTRATION: URL: https://trialsearch.who.int/ ; Unique identifier: NL7537.

Year:

2024

Background Blood-brain barrier (BBB) integrity is presumed to be impaired in hypertension, resulting from cerebral endothelial dysfunction. Hypertension antedates various cerebrovascular diseases, such as cerebral small vessel disease (cSVD), and is a risk factor for developing neurodegenerative diseases for which BBB disruption is a preceding pathophysiological process. In this study, we investigated the relation between hypertension, current blood pressure and BBB leakage in human subjects. Methods BBB leakage was determined in twenty-two patients with hypertension and nineteen normotensive controls, age- and sex-matched (median age[range]:65[45-80] years,19 males), using a sparsely time-sampled contrast-enhanced 7 Tesla MRI protocol. Structural cSVD markers were visually rated. Multivariable regression analyses, adjusted for age, sex, cardiovascular risk factors and cSVD markers, were performed to determine the relation between hypertension status, systolic and diastolic blood pressure (SBP and DBP), mean arterial pressure (MAP), drug treatment, and BBB leakage. Results Both hypertensive and normotensive participants showed mild scores of cSVD. BBB leakage did not differ between hypertensive and normotensive participants, however was significantly higher for SBP, DBP and MAP in the cortex, and DBP and MAP in the grey matter. Effectively treated patients showed less BBB leakage than those with current hypertension. Conclusion BBB integrity in the total and cortical grey matter decreases with increasing blood pressure, but is not related to hypertension status. These findings show that BBB disruption already occurs with increasing blood pressure, before the presence of overt cerebral tissue damage. Additionally, our results suggest that effective antihypertensive medication has a protective effect on the BBB. Registered at: https://trialsearch.who.int/ ; Unique identifier: NL7537

Year:

2024

Year:

2023

Year:

2023

Collaborators (27)

Abraham Kroon

Professor of Vascular Medicine

University of Maastricht

NETHERLANDS
View details

Harith Akram

Consultant neurosurgeon and Honorary Associate Professor

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

Jacobus F. A. Jansen

Eindhoven University of Technology

NETHERLANDS
View details

Ki Sueng Choi

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Robert Richardson

Director, Functional Neurosurgery

Massachusetts General Hospital

UNITED STATES
View details

Damon Verstappen

University of Maastricht

NETHERLANDS
View details

Ludvic Zrinzo

Professor of Neurosurgery., Head Unit of Functional Neurosurgery

UCL Institute of Neurology, University College London

UNITED KINGDOM
View details

stephan chabardes

Grenoble Alpes University Hospital

FRANCE
View details

Eileen Joyce

University College London

UNITED KINGDOM
View details

Sameer Sheth

Baylor College of Medicine

UNITED STATES
View details

Susan L Rossell

Swinburne University of Technology

AUSTRALIA
View details

David Castle

University of Tasmania

CANADA
View details

Bryan Strange

Profesor I3

Universidad Politécnica de Madrid

SPAIN
View details

David Linden

University of Maastricht

NETHERLANDS
View details

Christopher Butson

Associate Professor

University of Utah

UNITED STATES
View details

Martijn Figee

Associate Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Thomas Foltynie

University College London

UNITED KINGDOM
View details

José P. Marques

Senior Scientist

Radboud University

NETHERLANDS
View details

Alon Mogilner

Associate Professor (Clinical) of Anesthesiology, Perioperative Care and Pain Medicine and Neurosurgery (Academic)

NYU School of Medicine

UNITED STATES
View details

Gerhard Drenthen

University of Maastricht

NETHERLANDS
View details

Carsten Finke

Charité - Universitätsmedizin Berlin

GERMANY
View details

Christos Ganos

Director

-

GERMANY
View details

Walter H. Backes

-

NETHERLANDS
View details

Philip Mosley

Commonwealth Scientific and Industrial Research Organisation

AUSTRALIA
View details

Volodia Dangouloff-Ros

Inserm U1000

FRANCE
View details

Michael Okun

Member

Fixel Institute for Neurological Diseases

UNITED STATES
View details

Kara Johnson

Assistant Professor

University of Utah

UNITED STATES
View details